People are on the move at Baxter, Merck & Co., Johnson & Johnson, and elsewhere in this week's column.
A senior Baxter executive will move to Merck & Co. later this month to become executive VP and Chief Financial Officer (CFO).
Robert M. Davis, 47, is currently corporate VP and president of Baxter’s medical products business. The company announced last week it will separate its biopharmaceutical business from its medical products .
Davis will transfer to Merck & Co. on April 23, where he will spend a three-week handover period with his predecessor, Peter Kellogg. Kellogg has been MSD’s CFO since 2007.
In his new role, Davis will oversee corporate business development. He previously oversaw the integration of Baxter’s drug delivery and renal businesses into one division. He also served variously as the renal division’s CFO and treasurer, after working for 14 years at Eli Lilly.
For a guide to the differences between rival companies Merck & Co. (MSD) and Merck KGaA, see In-Pharmatechnologist’s handy timeline .
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...